Edition:
United States

Sinclair Pharma PLC (SPH.L)

SPH.L on London Stock Exchange

27.25GBp
12:15pm EDT
Change (% chg)

0.50p (+1.87%)
Prev Close
26.75p
Open
26.75p
Day's High
27.50p
Day's Low
26.50p
Volume
1,829,824
Avg. Vol
737,130
52-wk High
41.50p
52-wk Low
26.00p

SPH.L

Chart for SPH.L

About

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and... (more)

Overall

Beta: 0.19
Market Cap(Mil.): £133.06
Shares Outstanding(Mil.): 497.42
Dividend: --
Yield (%): --

Financials

  SPH.L Industry Sector
P/E (TTM): -- 37.66 37.54
EPS (TTM): -0.05 -- --
ROI: -12.56 14.54 13.98
ROE: -23.37 15.32 14.88

BRIEF-Sinclair Pharma on track to meet 2016 sales guidance

* Group revenues increased 125 pct to £17.3 million compared to 7.7 million stg in previous six month period

Sep 21 2016

BRIEF-Sinclair Pharma says Christophe Foucher has stepped down from board

* Christophe foucher, chief operating officer, has stepped down from board with immediate effect Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

Sep 01 2016

BRIEF-Sinclair Pharma says second interim period revenues of 17.2 mln stg

* In second interim period, sinclair increased revenues to £17.2m, compared to £7.7m in first interim period

Jul 19 2016

BRIEF-Almirall signs US distribution deal with Sinclair Pharma

* Signs through its Dallas based company Thermigen, an exclusive US strategic marketing collaboration agreement for Silhouette Instalift (TM) with Sinclair Pharma Plc

May 23 2016

BRIEF-Sinclair Pharma expects to deliver 40 pct FY rev growth

* Sinclair continues to expect to deliver 40% revenue growth in calendar 2016

May 20 2016

BRIEF-Sinclair Pharma sees Q3 revenue to exceed 8 mln stg

* As expected, reported sales at 7.7 mln stg (H1 FY15: 10.5 mln stg) were lower in H1 as a result of planned distributor de-stocking

Mar 30 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Peel Hunt
$23.00
Provider : Sadif Analytics Prime
$25.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.